Twist Bioscience CEO sells 6,888 shares for taxes
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported a mandated sale of 6,888 shares of Common Stock on May 21, 2026 at an average price of $53.257 per share.
Rhea-AI Filing Summary
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported a mandated sale of 6,888 shares of Common Stock on May 21, 2026 at an average price of $53.257 per share. According to the disclosure, these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units under the company’s equity incentive plans, and the transaction did not represent a discretionary trade by the CEO. Following this transaction, Leproust directly held 846,872 shares of Twist Bioscience Common Stock and retained employee stock options covering 64,950 underlying shares at an exercise price of $67.85 per share, expiring on August 31, 2030.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 6,888 | $53.257 | $367K |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
Footnotes (6)
- F1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- F2. The option is immediately exercisable. 25% of the shares subject to the option vested on September 1, 2016 and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F3. The option is immediately exercisable. 10% of the shares subject to the option vested on September 28, 2017, 15% of the shares subject to the option vested on September 28, 2018, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F4. 20% of the shares subject to the option vested and became exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F5. 25% of the shares subject to the option vested on October 24, 2020, and 1/48th of the shares subject to the option vest on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
- F6. Represents performance stock options granted to the reporting person on September 1, 2020, that vested and became exercisable on December 19, 2022 as a result of the reporting person having met the applicable performance criteria.
Key Figures
Key Terms
Restricted Stock Units financial
sell to cover financial
equity incentive plans financial
Employee Stock Option (right to buy) financial
performance stock options financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Twist Bioscience (TWST) CEO Emily Leproust report in this Form 4?
What stock options does the Twist Bioscience (TWST) CEO still hold?
AI-generated analysis. How Rhea-AI works. Not financial advice.